SCHEMBL4761809

SCHEMBL4761809

Cc1cc(NCC(=O)O)ccc1O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
MAPT P10636 2/20 0.44
AGTR1 P30556 2/20 0.44
GAA P10253 1/20 0.44
ERCC1 P07992 1/20 0.44
ERCC4 Q92889 1/20 0.44
TDP1 Q9NUW8 2/20 0.42
LMNA P02545 1/20 0.42
EGFR P00533 1/20 0.42
HSP90AA1 P07900 1/20 0.41
HSP90AB1 P08238 1/20 0.41
ESR1 P03372 1/20 0.41
ESR2 Q92731 1/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA7 P43166 1/20 0.41
TP53 P04637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15933411 0.86 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MAPTAGTR1GAA
SCHEMBL21518479 0.85 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MAPTAGTR1GAA
SCHEMBL851008 0.83 ERCC1 (0.60) ALDH1A1MAPTGAAERCC1ERCC4
Water SCHEMBL9710740 0.81 ERCC1 (0.58) ALDH1A1MAPTGAAERCC1ERCC4
SCHEMBL14053068 0.81 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MAPTAGTR1GAA
SCHEMBL16104668 0.81 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPTAGTR1GAA
SCHEMBL879821 0.81 MAPT (0.57) ALDH1A1SMN1; SMN2MAPTGAATDP1
SCHEMBL3142563 0.80 POLB (0.54) TDP1LMNAEGFRHSP90AA1HSP90AB1
SCHEMBL16585968 0.79 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTAGTR1GAA
SCHEMBL11532507 0.79 THRA (0.46) ALDH1A1MAPTERCC1ERCC4TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120238750-A1 AROMATIC COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2012-09-20 US disclosed
EP-1957073-A2 MEDICINAL DRUG OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-08-20 EP disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
EP-0437566-B1 PHENYL-GLYCINE DERIVATIVES CHINOIN GYOGYSZER ES VEGYESZET (HU) 1994-09-28 EP disclosed
US-5338868-A Reacting glycine derivative with trifluoro methane sulfonic acid derivative at low temperature CHINOIN GYOGYSZER- ES VEGYESZETI TERMEKEK GYARA RT. (HU) 1994-08-16 US disclosed
EP-0437566-A1 PHENYL-GLYCINE DERIVATIVES. CHINOIN GYOGYSZER ES VEGYESZET (HU) 1991-07-24 EP disclosed
WO-1991001968-A1 PHENYL-GLYCINE DERIVATIVES CHINOIN GYÓGYSZER ÉS VEGYÉSZETI TERMÉKEK GYÁRA RT (HU) 1991-02-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120238750-A1 AROMATIC COMPOUND CBR1, CBR3, CYP1A1 ALDH1A1 565/4885SMN1; SMN2 4313/4885MAPT 4315/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.